SG11201501911RA - Methods of treating epilepsy or status epilepticus - Google Patents

Methods of treating epilepsy or status epilepticus

Info

Publication number
SG11201501911RA
SG11201501911RA SG11201501911RA SG11201501911RA SG11201501911RA SG 11201501911R A SG11201501911R A SG 11201501911RA SG 11201501911R A SG11201501911R A SG 11201501911RA SG 11201501911R A SG11201501911R A SG 11201501911RA SG 11201501911R A SG11201501911R A SG 11201501911RA
Authority
SG
Singapore
Prior art keywords
methods
status epilepticus
treating epilepsy
epilepsy
treating
Prior art date
Application number
SG11201501911RA
Inventor
Kiran Reddy
Stephen Jay Kanes
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of SG11201501911RA publication Critical patent/SG11201501911RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Fire-Extinguishing Compositions (AREA)
  • Gasification And Melting Of Waste (AREA)
  • Carbon And Carbon Compounds (AREA)
SG11201501911RA 2012-08-21 2013-08-21 Methods of treating epilepsy or status epilepticus SG11201501911RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691545P 2012-08-21 2012-08-21
US201361789491P 2013-03-15 2013-03-15
PCT/US2013/056062 WO2014031792A2 (en) 2012-08-21 2013-08-21 Methods of treating epilepsy or tatus epilepticus

Publications (1)

Publication Number Publication Date
SG11201501911RA true SG11201501911RA (en) 2015-04-29

Family

ID=50148516

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201501911RA SG11201501911RA (en) 2012-08-21 2013-08-21 Methods of treating epilepsy or status epilepticus
SG10201608148TA SG10201608148TA (en) 2012-08-21 2013-08-21 Methods Of Treating Epilepsy Or Status Epilepticus

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201608148TA SG10201608148TA (en) 2012-08-21 2013-08-21 Methods Of Treating Epilepsy Or Status Epilepticus

Country Status (27)

Country Link
US (4) US20140057885A1 (en)
EP (2) EP3957309A1 (en)
JP (3) JP6355633B2 (en)
KR (2) KR102121633B1 (en)
CN (2) CN111529537A (en)
AU (4) AU2013305767B2 (en)
BR (2) BR122021022560B1 (en)
CA (1) CA2882708A1 (en)
CY (1) CY1125070T1 (en)
DK (1) DK2887944T3 (en)
ES (1) ES2902684T3 (en)
HK (1) HK1209025A1 (en)
HR (1) HRP20220005T1 (en)
HU (1) HUE056838T2 (en)
IL (5) IL275725B (en)
LT (1) LT2887944T (en)
MX (1) MX2015002252A (en)
NZ (1) NZ705410A (en)
PH (2) PH12015500482A1 (en)
PL (1) PL2887944T3 (en)
PT (1) PT2887944T (en)
RS (1) RS62761B1 (en)
RU (2) RU2018132041A (en)
SG (2) SG11201501911RA (en)
SI (1) SI2887944T1 (en)
WO (1) WO2014031792A2 (en)
ZA (1) ZA201501188B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101405545B1 (en) 2005-11-28 2014-07-03 마리누스 파마슈티컬스 Ganaxolone formulations and methods for the making and use thereof
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
LT2806877T (en) * 2012-01-23 2019-12-10 Sage Therapeutics Inc Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
EP2925327B1 (en) 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
WO2016036724A1 (en) 2014-09-02 2016-03-10 The Texas A&M University System Method of treating organophosphate intoxication
JOP20200195A1 (en) * 2014-09-08 2017-06-16 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
TW202235090A (en) 2014-10-16 2022-09-16 美商賽吉醫療公司 Compositions and methods for treating cns disorders
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
PT3229790T (en) 2014-12-08 2020-01-22 Nestle Sa Compositions and methods comprising medium chain triglycerides for treatment of epilepsy
US10668041B2 (en) 2014-12-08 2020-06-02 Societe Des Produits Nestle Sa Compositions and methods comprising medium chain triglycerides for treatment of epilepsy
EP3253418A1 (en) * 2015-02-06 2017-12-13 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
CN107249586A (en) * 2015-02-17 2017-10-13 万达制药公司 For treating schizoid Iloperidone
MA45276A (en) 2015-06-18 2018-04-25 Sage Therapeutics Inc NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE
JP2018530585A (en) 2015-10-16 2018-10-18 マリナス ファーマシューティカルズ インコーポレイテッド Injectable neurosteroid preparation containing nanoparticles
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CA3030420A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
IL264129B2 (en) 2016-07-11 2024-05-01 Sage Therapeutics Inc C17, c20, and c21 substituted neuroactive steroids and their methods of use
KR102518846B1 (en) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. Methods and compositions for the treatment of epileptic disorders
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2019051477A1 (en) * 2017-09-11 2019-03-14 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
WO2019075362A1 (en) 2017-10-12 2019-04-18 Sage Therapeutics, Inc. Method of treating cns disorders with neurosteroids and gabaergic compounds
WO2019094724A1 (en) * 2017-11-10 2019-05-16 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disoders
EP3886856A4 (en) * 2018-11-29 2022-01-19 Zucco Sassi Yonezawa Siviglia, Debora Method for treating or preventing seizures associated with an epileptic disorder
US11446262B2 (en) 2018-11-29 2022-09-20 Debora Zucco Sassi Yonezawa Siviglia Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
MX2022001553A (en) 2019-08-05 2022-04-18 Marinus Pharmaceuticals Inc Ganaxolone for use in treatment of status epilepticus.
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
MX2022006014A (en) 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolone for use in treating tuberous sclerosis complex.
CN113368084A (en) * 2020-03-10 2021-09-10 上海喀露蓝科技有限公司 Pharmaceutical composition containing cannabidiol, propofol prodrug and allopregnanolone prodrug compound and application of pharmaceutical composition in medicines
IL296645A (en) 2020-03-25 2022-11-01 Sage Therapeutics Inc Use of agents for treatment of respiratory conditions
EP4157250A1 (en) * 2020-05-29 2023-04-05 Cerecin Inc. Methods for the treatment of infantile spasms using medium chain triglycerides
CN113925832B (en) * 2020-07-13 2023-06-16 苏州特瑞药业股份有限公司 Allopregnanolone liposome and preparation method thereof
WO2022109440A1 (en) * 2020-11-23 2022-05-27 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of super refractory status epilepticus
WO2023060020A1 (en) * 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of established status epilepticus

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5847009A (en) 1986-01-14 1998-12-08 Alliance Pharmaceutical Corp. Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
CN1171114A (en) * 1994-11-23 1998-01-21 科斯赛斯公司 Androstane and preg nane series for allosteric modulation of gamma-amino-butyric acid receptor
US6780853B1 (en) * 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
PT839525E (en) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd PROLONGED LIBERATION PREPARATION
US7630757B2 (en) * 1997-01-06 2009-12-08 Flint Hills Scientific Llc System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6316613B1 (en) 1997-07-25 2001-11-13 Beckman Coulter, Inc. Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis
US6442887B2 (en) 2000-02-25 2002-09-03 Robert L. Sanquist Live bait keeper
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
GR1003861B (en) * 2000-12-29 2002-04-11 Novel gabaa modulating neurosteroids
CA2472184C (en) 2002-01-14 2011-04-19 David Mark Lucas Magnetically detectable latex articles
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
US7781421B2 (en) 2003-05-29 2010-08-24 Washington University Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods
US7816074B2 (en) * 2003-07-31 2010-10-19 The Research Foundation Of State University Of New York α4 β2 δGABA-A receptors as a strategy for PMS and alcoholism
ITMI20041763A1 (en) 2004-09-16 2004-12-16 Altergon Sa NEW INJECTABLE FORMULATIONS CONTAINING PROGESTERONE
US8557861B2 (en) 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
EP1868614B1 (en) * 2005-03-24 2012-08-08 Emory University Dosage regimen for the treatment of a traumatic brain injury with progesterone
EP1868593A2 (en) * 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
US20090074677A1 (en) * 2007-01-08 2009-03-19 Duke University Neuroactive steroid compositions and methods of use therefor
AU2008265898B2 (en) 2007-06-15 2013-11-28 Research Triangle Institute Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties
EP2173169B1 (en) * 2007-06-28 2014-05-21 CyDex Pharmaceuticals, Inc. Nasal delivery of aqueous corticosteroid solutions
DE102008015366A1 (en) 2008-03-20 2009-09-24 Merck Patent Gmbh Lyophilised nanoemulsion
WO2010063030A2 (en) * 2008-11-30 2010-06-03 Feigelson, Daniel Dermal application of vasoconstrictors
CA2732437C (en) * 2008-08-01 2017-11-21 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
CN106243100B (en) * 2008-10-10 2019-04-09 Vm生物医药公司 Treat alcohol use disorders, the pharmaceutical composition and method of pain and other diseases
US20110306579A1 (en) * 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
PL2525798T3 (en) * 2010-01-21 2018-05-30 Drawbridge Pharmaceuticals Pty Ltd. Anaesthetic formulation
BR112013010342A8 (en) * 2010-11-03 2018-04-03 Sanofi Aventis Deutschland module containing medicine and needle cannula
WO2012075286A2 (en) * 2010-12-01 2012-06-07 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
FR2973031B1 (en) 2011-03-23 2013-11-29 Univ Strasbourg DERIVATIVES OF ALLOPREGNANOLONE AND EPIALLOPREGNANOLONE AND USES THEREOF FOR TREATING A NEUROPATHOLOGICAL CONDITION
LT2806877T (en) * 2012-01-23 2019-12-10 Sage Therapeutics Inc Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
WO2014028398A2 (en) * 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids

Also Published As

Publication number Publication date
IL275725B (en) 2022-08-01
HRP20220005T1 (en) 2022-04-01
US20190038639A1 (en) 2019-02-07
RU2015109956A (en) 2016-10-20
US20190269699A1 (en) 2019-09-05
AU2018220028B2 (en) 2020-04-02
US20140057885A1 (en) 2014-02-27
EP2887944A4 (en) 2016-02-10
JP6355633B2 (en) 2018-07-11
NZ705410A (en) 2018-03-23
JP2015527371A (en) 2015-09-17
AU2018220028A1 (en) 2018-09-06
ZA201501188B (en) 2016-09-28
PH12020500065A1 (en) 2021-04-26
PL2887944T3 (en) 2022-02-21
IL264414B (en) 2020-07-30
BR112015003747A2 (en) 2017-07-04
AU2020204359A1 (en) 2020-07-23
IL294306B1 (en) 2023-09-01
PH12015500482A1 (en) 2015-04-20
KR102121633B1 (en) 2020-06-10
IL264414A (en) 2019-02-28
ES2902684T3 (en) 2022-03-29
IL237352A0 (en) 2015-04-30
MX2015002252A (en) 2015-07-21
AU2013305767B2 (en) 2018-05-24
EP2887944B1 (en) 2021-10-06
EP2887944A2 (en) 2015-07-01
RS62761B1 (en) 2022-01-31
AU2013305767A1 (en) 2015-03-19
CN104736159A (en) 2015-06-24
IL237352B (en) 2019-05-30
LT2887944T (en) 2022-01-10
AU2022202277A1 (en) 2022-04-21
KR20200067922A (en) 2020-06-12
BR122021022560B1 (en) 2022-08-09
RU2018132041A3 (en) 2022-03-31
IL275725A (en) 2020-08-31
JP2021059608A (en) 2021-04-15
CN111529537A (en) 2020-08-14
HUE056838T2 (en) 2022-04-28
EP3957309A1 (en) 2022-02-23
IL294306B2 (en) 2024-01-01
US20220152050A1 (en) 2022-05-19
KR20150054846A (en) 2015-05-20
SG10201608148TA (en) 2016-11-29
WO2014031792A3 (en) 2014-04-10
PT2887944T (en) 2022-01-10
RU2018132041A (en) 2018-11-13
IL304912A (en) 2023-10-01
JP6829224B2 (en) 2021-02-10
KR102305359B1 (en) 2021-09-24
WO2014031792A2 (en) 2014-02-27
HK1209025A1 (en) 2016-03-24
CA2882708A1 (en) 2014-02-27
DK2887944T3 (en) 2022-01-03
CY1125070T1 (en) 2023-06-09
JP2018154652A (en) 2018-10-04
SI2887944T1 (en) 2022-02-28
IL294306A (en) 2022-08-01
RU2667010C2 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
IL294306A (en) Methods of treating epilepsy or status epilepticus
HK1213771A1 (en) Methods of treating cancer
HK1219414A1 (en) Methods of treating arthritis
HK1216393A1 (en) Methods of treating gastrointestinal spasms
HK1210962A1 (en) Methods for treatment of atherosclerosis
EP2892536A4 (en) Method of treating leukemia
IL260115A (en) Methods of treating fibrosis
HRP20181000T1 (en) Methods of treating hair related conditions
HK1209040A1 (en) Methods for treating vestibulotoxicity
PT2811993T (en) Methods of treating fibrosis
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201221032D0 (en) Method of treatment
GB201207894D0 (en) Method of treatment